Online ISSN: 3007-0244,
Print ISSN:  2410-4280
CLINICAL EFFICACY OF THE ANTIVIRAL DRUG FAVIPIRAVIR IN THE COMPLEX TREATMENT OF PATIENTS WITH COVID-19 CORONAVIRUS INFECTION
Introduction. It is known that most patients with COVID-19 have a disease of mild to moderate severity and can be treated at home. A potential etiotropic drug in the treatment of such patients is favipiravir. To finally decide on the inclusion of this drug in the international recommendations for the treatment of COVID-19, further studies are needed to assess its effectiveness and safety in patients with COVID-19. The aim of the study was to study the clinical efficacy of favipiravir in the complex therapy of patients with moderate-severity COVID-19 coronavirus infection. Materials and methods. A retrospective analysis of 468 medical records of an inpatient patient with a moderate form of coronavirus infection COVID-19, who were treated at the State Clinical Hospital at the Multi-Specialty Medical Center of the Akimat of Nur-Sultan, the Semey Infectious Diseases Hospital, for the period August-October 2020, was carried out. The experimental (main) group consisted of 40 patients with COVID-19 of moderate severity, who, in addition to standard therapy in accordance with the Clinical Protocol for Diagnosis and Treatment "COVID-19 Coronavirus infection (10th edition with changes from 15.07.2020), were prescribed oral favipiravir at a dose of 1600 mg/12 h on day 1, then 600 mg/12 h on the following days, for a total of 7 days. The comparison group (control group) consisted of 40 patients with moderate CVI who did not receive favipiravir. Descriptive statistics were performed with the calculation of the mean (M) and standard deviation (SD) for quantitative variables; percentages were calculated for qualitative variables. Statistical analysis was performed using Microsoft Excel and IBM SPSS Statistics 20.0. P <0.05 was considered statistically significant. Results and discussion. The present study showed that the early initiation of antiviral therapy with Favipiravir, compared with standard therapy without an antiviral drug, in patients with a moderate form of COVID-19 is associated with a statistically significant clinical improvement and a large percentage of virus elimination from the mucous membranes of the upper respiratory tract according to molecular genetic research. In the group of patients receiving favipiravir, complete remission of the disease with normalization of the main clinical parameters and the absence of complaints for 7 days of hospitalization was significantly more often than in the comparison group. Conclusions. The results obtained showed that Favipiravir is an effective antiviral drug in the complex treatment of COVID-19 coronavirus infection of moderate severity. Early administration of the drug in patients with a moderate form of the disease can prevent the progression of the disease to a more severe condition and the development of complications that require additional medical interventions.
Sholpan A. Kulzhanova1, https://orcid.org/000-0002-4118-4905 Nurlan Е. Aukenov 2, https://orcid.org/0000-0002-3163-2997 Maiya E. Konkayeva1, https://orcid.org/0000-0002-1634-3855 Zauresh K. Smagulova1, Gulnara T. Tuleshova1, https://orcid.org/0000-0002-7309-5165 Saule B. Maukayeva3, http://orcid.org/ 0000-0002-2679-6399 Nazira Ye. Beisenbieva1, Gulsimzhan O. Turebaeva1, Gaukhar A. Nurakhmetova1, https://orcid.org/ 0000-0002-3279-9350 Aigul M. Utegenova1, https://orcid.org/ 0000-0002-5777-3747 1 NJSC “Astana Medical University”, Nur-Sultan, Republic of Kazakhstan; 2 Ministry of Health of the Republic of Kazakhstan, Nur-Sultan, Republic of Kazakhstan; 3 NJSC “Semey Medical University”, Semey, Republic of Kazakhstan.
1. Agrawal U., Raju R., Udwadia Z.F. Favipiravir: A new and emerging antiviral option in COVID-19. Medical Journal Armed Forces India. Elsevier B.V. 2020, October 1. https://doi.org/10.1016/j.mjafi.2020.08.004 2. Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K. and Yuan S. Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan // Emerg Microbes Infect 2020; 9(1): 221-36. 3. Chen Y., Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication and pathogenesis // J Med Virol 2020; 92(4): 418-23. 4. Clinical protocol "Coronavirus infection COVID-19", approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan dated July 15, 2020. No. 106. 5. Delang L., Abdelnabi R., Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral research, 2018. 153, 85–94. https://doi.org/10.1016/j.antiviral.2018.03.003 6. Erdem H.A., Korkma P.E., Çağlayan D., Işıkgöz Taşbakan M., Yamazhan T., Taşbakan M.S., Sayıner A., Gökengin D. Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turkishjournalofmedicalsciences, 2021. 51(3), 912–920. https://doi.org/10.3906/sag-2008-33 7. Eroglu E., Toprak G. Overview of favipiravir and remdesivir treatment for COVID-19 // International Journal of Pharmaceutical Sciences and Research, 2021; Vol. 12(4): 1950-1957. 8. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research, 2013. 100(2), 446–454. https://doi.org/10.1016/j.antiviral.2013.09.015 9. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46:977–981. [PubMed: 11897578] 10. Ghasemnejad-Berenji M., Pashapour S. Favipiravir and COVID-19: A Simplified Summary. Drug research, 2021. 71(3), 166–170. https://doi.org/10.1055/a-1296-7935 11. Gowen B.B., Smee D.F., Wong M.H., Hall J.O., Jung K.H., Bailey K.W., Stevens J.R., Furuta Y., Morrey J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PloS one, 20083. 11, e3725. https://doi.org/10.1371/journal.pone.0003725 12. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., Sidwell R.W. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrobial agents and chemotherapy, 2007. 51(9), 3168–3176. https://doi.org/10.1128/AAC.00356-07 13. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research, 2020. 7(1). https://doi.org/10.1186/s40779-020-00240-0 14. Hassanipour S., Arab-Zozani M., Amani B., Heidarzad F., Fathalipour M., Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Scientific reports, 2021. 11(1), 11022. https://doi.org/10.1038/s41598-021-90551-6 15. Hayden F.G., Shindo N. Influenza virus polymerase inhibitors in clinical development. Current opinion in infectious diseases, 2019. 32(2), 176–186. https://doi.org/10.1097/QCO.0000000000000532 16. Julander J.G., Shafer K., Smee D.F., Morrey J.D., Furuta Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrobial agents and chemotherapy, 2009. 53(1), 202–209. https://doi.org/10.1128/AAC.01074-08 17. Julander J.G., Smee D.F., Morrey J.D., Furuta Y. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral research, 2009. 82(3), 169–171. https://doi.org/10.1016/j.antiviral.2009.02.201 18. Łagocka R., Dziedziejko V., Kłos P., Pawlik A. Favipiravir in Therapy of Viral Infections. Journal of clinical medicine, 2021. 10(2), 273. https://doi.org/10.3390/jcm10020273 19. Majumder J., Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. The AAPS Journal, 2021. 23(1). https://doi.org/10.1208/s12248-020-00532-2 20. Manabe T., Kambayashi D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC infectious diseases, 2021. 21(1), 489. https://doi.org/10.1186/s12879-021-06164-x 21. Mehta N., Mazer-Amirshahi M., Alkindi N., Pourmand A. Pharmacotherapy in COVID-19; A narrative review for emergency providers. The American Journal of Emergency Medicine, 2020. 38(7), 1488–1493. https://doi.org/10.1016/j.ajem.2020.04.035 22. Morrey J.D., Taro B.S., Siddharthan V., Wang H., Smee D.F., Christensen A.J., Furuta Y. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral research, 2008. 80(3), 377–379. https://doi.org/10.1016/j.antiviral.2008.07.009 23. Nagata T., Lefor A.K., Hasegawa M., Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster medicine and public health preparedness, 2015, 9(1), 79–81. https://doi.org/10.1017/dmp.2014.151 24. Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K. and Singh A.: Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach // Biochim Biophys Acta Mol Basis Dis 2020; 1866(10): 165878. 25. Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K. and Singh A.: Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach // Biochim Biophys Acta Mol Basis Dis 2020; 1866(10): 165878. 26. Nasir M., Perveen R.A., Saha S.K., Talha K.A., Selina F., Islam M.A. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2. Mymensingh medical journal: MMJ, 2020. 29(3), 747–754. 27. Pascarella G., Strumia A., Piliego C., Bruno F., Del Buono R. and Costa F. COVID-19 diagnosis and management: a comprehensive review // J Int Med 2020; 288(2): 192 206. 28. Rocha-Pereira J., Jochmans D., Dallmeier K., Leyssen P., Nascimento M.S., Neyts J. Favipiravir (T-705) inhibits in vitro norovirus replication // Biochemical and biophysical research communications, 2012. 424(4), 777–780. https://doi.org/10.1016/j.bbrc.2012.07.034 29. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics, 2020. 209, 107512. https://doi.org/10.1016/j.pharmthera.2020.107512 30. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology & therapeutics, 2020. 209, 107512. https://doi.org/10.1016/j.pharmthera.2020.107512 31. Shrestha D.B., Budhathoki P., Khadka S., Shah, P.B., Pokharel N., Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology journal, 2020. 17(1), 141. https://doi.org/10.1186/s12985-020-01412-z 32. Sreekanth Reddy O., Lai W.F. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. Chembiochem : a European journal of chemical biology, 2021. 22(6), 939–948. https://doi.org/10.1002/cbic.202000595 33. Udwadia Z.F., Singh P., Barkate H., Patil S., Rangwala S., Pendse A., Kadam J., Wu W., Caracta C. F., Tandon M. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases, 2021. 103, 62–71. https://doi.org/10.1016/j.ijid.2020.11.142 21. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro // Cell research, 2020. 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0 34. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 2020. 30(3), 269–271. https://doi.org/10.1038/s41422-020-0282-0 35. Yamamura H., Matsuura H., Nakagawa J., Fukuoka H., Domi H., Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Critical Care, 2020. 24(1). https://doi.org/10.1186/s13054-020-03137-5 36. Zeitlinger M., Koch B.C.P., Bruggemann R., De Cock P., Felton T., Hites M., Le J., Luque S., Macgowan A. P., Marriott D.J.E., Muller A.E., Nadrah K., Paterson D.L., Standing J.F., Telles J.P., Wölfl-Duchek M., Thy M., Roberts J.A. Pharmacokinetics / Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicr. Clinical Pharmacokinetics, 2020. 59(10), 1195–1216. https://doi.org/10.1007/s40262-020-00924-9
Количество просмотров: 541

Ключевые слова:

Категория статей: Актуальная тема COVID-19

Библиографическая ссылка

Kulzhanova Sh.A., Aukenov N.Е., Konkayeva M.E., Smagulova Z.K., Tuleshova G.T., Maukaeva C.B., Beisenbieva N.Ye., Turebaeva G.O., Nurakhmetova G.A., Utegenova A.M. Clinical efficacy of the antiviral drug Favipiravir in the complex treatment of patients with COVID-19 coronavirus infection // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, 4 (Vol.23), pp. 6-15. doi 10.34689/SH.2021.23.4.001

Авторизируйтесь для отправки комментариев